Coherus Oncology (CHRS) Competitors $0.88 -0.06 (-6.64%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.89 +0.01 (+1.50%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CHRS vs. KOD, PGEN, PRTC, RGNX, SVRA, KMDA, CMPX, PVLA, FULC, and GOSSShould you be buying Coherus Oncology stock or one of its competitors? The main competitors of Coherus Oncology include Kodiak Sciences (KOD), Precigen (PGEN), PureTech Health (PRTC), REGENXBIO (RGNX), Savara (SVRA), Kamada (KMDA), Compass Therapeutics (CMPX), Palvella Therapeutics (PVLA), Fulcrum Therapeutics (FULC), and Gossamer Bio (GOSS). These companies are all part of the "pharmaceutical products" industry. Coherus Oncology vs. Its Competitors Kodiak Sciences Precigen PureTech Health REGENXBIO Savara Kamada Compass Therapeutics Palvella Therapeutics Fulcrum Therapeutics Gossamer Bio Coherus Oncology (NASDAQ:CHRS) and Kodiak Sciences (NASDAQ:KOD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability. Do institutionals & insiders have more ownership in CHRS or KOD? 72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 89.1% of Kodiak Sciences shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Comparatively, 45.9% of Kodiak Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to CHRS or KOD? In the previous week, Coherus Oncology had 3 more articles in the media than Kodiak Sciences. MarketBeat recorded 3 mentions for Coherus Oncology and 0 mentions for Kodiak Sciences. Coherus Oncology's average media sentiment score of 0.25 beat Kodiak Sciences' score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the media. Company Overall Sentiment Coherus Oncology Neutral Kodiak Sciences Neutral Do analysts prefer CHRS or KOD? Coherus Oncology presently has a consensus price target of $4.68, indicating a potential upside of 433.53%. Kodiak Sciences has a consensus price target of $9.00, indicating a potential upside of 35.34%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Coherus Oncology is more favorable than Kodiak Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Kodiak Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better valuation and earnings, CHRS or KOD? Coherus Oncology has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus Oncology$272.25M0.37$28.51M-$1.13-0.78Kodiak SciencesN/AN/A-$176.21M-$3.63-1.83 Which has more volatility & risk, CHRS or KOD? Coherus Oncology has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Kodiak Sciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. Is CHRS or KOD more profitable? Kodiak Sciences has a net margin of 0.00% compared to Coherus Oncology's net margin of -66.30%. Coherus Oncology's return on equity of 0.00% beat Kodiak Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Coherus Oncology-66.30% N/A -26.51% Kodiak Sciences N/A -115.71%-54.17% SummaryCoherus Oncology beats Kodiak Sciences on 11 of the 15 factors compared between the two stocks. Get Coherus Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRS vs. The Competition Export to ExcelMetricCoherus OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$109M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-0.7817.6228.6723.80Price / Sales0.37179.18373.9066.58Price / Cash3.2341.9535.4557.96Price / Book-0.778.508.275.55Net Income$28.51M-$55.06M$3.24B$259.03M7 Day Performance-15.60%-3.98%-3.69%-4.59%1 Month Performance10.40%9.59%4.33%4.46%1 Year Performance-34.98%6.72%25.95%18.03% Coherus Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHRSCoherus Oncology3.8227 of 5 stars$0.88-6.6%$4.68+433.5%-38.6%$109M$272.25M-0.78330News CoverageUpcoming EarningsKODKodiak Sciences3.3197 of 5 stars$8.24-6.8%$9.00+9.2%+130.1%$466.43MN/A-2.2790PGENPrecigen3.9979 of 5 stars$1.58+0.6%$6.00+279.7%+16.8%$463.43M$3.92M-2.82190News CoveragePositive NewsOptions VolumePRTCPureTech Health1.427 of 5 stars$19.09+0.1%$45.00+135.8%-12.1%$458.15M$4.83M0.00100Gap DownRGNXREGENXBIO4.1235 of 5 stars$8.79-1.9%$31.63+259.8%-38.5%$449.44M$83.33M-2.83370News CoverageUpcoming EarningsGap DownSVRASavara1.4861 of 5 stars$2.66+3.1%$5.60+110.5%-43.0%$445.92MN/A-5.5420High Trading VolumeKMDAKamada4.488 of 5 stars$7.68-0.5%$13.00+69.3%+30.3%$443.94M$160.95M26.48360News CoverageGap UpCMPXCompass Therapeutics2.3779 of 5 stars$3.20+0.6%$12.67+295.8%+196.2%$439.74M$850K-7.8020Positive NewsPVLAPalvella Therapeutics2.6822 of 5 stars$39.87+3.2%$47.50+19.1%N/A$426.97M$42.81M-3.30N/AFULCFulcrum Therapeutics2.2669 of 5 stars$7.81flat$6.29-19.5%-24.2%$421.58M$80M-111.56100Trending NewsEarnings ReportAnalyst UpgradeAnalyst RevisionGOSSGossamer Bio3.9096 of 5 stars$1.98+7.6%$8.25+316.7%+127.3%$418.24M$114.70M-8.61180News CoverageOptions Volume Related Companies and Tools Related Companies Kodiak Sciences Alternatives Precigen Alternatives PureTech Health Alternatives REGENXBIO Alternatives Savara Alternatives Kamada Alternatives Compass Therapeutics Alternatives Palvella Therapeutics Alternatives Fulcrum Therapeutics Alternatives Gossamer Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CHRS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coherus Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
